Nathan T. Ihle
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Protein Kinase Regulation and GTPase Signaling, Monoclonal and Polyclonal Antibodies Research, PI3K/AKT/mTOR signaling in cancer, Computational Drug Discovery Methods
Most-Cited Works
- → Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome(2012)525 cited
- → Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling(2004)311 cited
- → Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer(2017)283 cited
- → Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance(2008)273 cited
- → Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy(2009)168 cited
- → Stability of Phosphoprotein as a Biological Marker of Tumor Signaling(2005)168 cited
- → The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts(2005)150 cited
- → Discovery of a novel class of AKT pleckstrin homology domain inhibitors(2008)80 cited
- → Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor(2010)76 cited
- → In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316(2004)52 cited